Non-contrast imaging characteristics of papillary renal cell carcinoma: implications for diagnosis and subtyping.

Non-contrast imaging characteristics of papillary renal cell carcinoma: implications for diagnosis and subtyping. Can J Urol. 2019 Oct;26(5):9916-9921 Authors: Badri AV, Waingankar N, Edwards K, Kutikov A, Parsons RB, Chen DY, Smaldone MC, Viterbo R, Greenberg RE, Uzzo RG Abstract INTRODUCTION: Current radiographic guidelines suggest unenhanced renal lesions
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research

Related Links:

CONCLUSION: Nivolumab demonstrated activity in unclassified nccRCC and ccRCC with>20% rhabdoid; further randomized clinical trials are warranted. IMPLICATIONS FOR PRACTICE: This article reports on the clinical activity and safety of immune checkpoint inhibitors in non-clear cell kidney cancer. The retrospective data with the meta-analysis provides a summary that will help guide the treatment of this rare and heterogeneous group of kidney cancers. PMID: 31501271 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Conclusions The recent, first randomized clinical trial demonstrated overall and progression free survival benefits after SBRT to oligometastatic disease which supports prior retrospective case series (6). The spine is a common site of metastatic bone disease, and as high quality data continue to mature, along with completion of additional randomized clinical trials, it is expected that utility of SBRT to the spine will increase in the future. Spine SBRT is unique due to the requirement of sharp dose falloff to prevent serious neurologic morbidity. With recent advances in radiotherapy planning, robotic patient positionin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsDOACs can be safely administered to patients with brain tumors. In patients with primary brain tumors (i.e. glioma), DOACs appear to be safer than LMWH and should be considered for this indication.Figure.DisclosuresZwicker: Incyte: Research Funding; Parexel: Consultancy; Quercegen: Research Funding; Daiichi: Honoraria.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
ConclusionsWe attempt to raise awareness, discuss early management strategies and hypothesize an association between the incidence and development of these adverse events in cancer patients treated with anti-PD-1 immunotherapeutic agents.
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Abstract In contrast to chemotherapy, treatment with immune checkpoint inhibitors occasionally results in an unconventional pattern of response. Besides an early partial or complete response or tumor progression, a so-called pseudoprogression, a "mixed response" or late responses can also be observed. Treatment beyond radiographically defined progression may therefore be appropriate in selected cases. For these treatment decisions, the clinical evaluation of the patient (performance status, symptoms, etc.), the "dynamics" of the underlying malignancy, and the availability of other tre...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
ConclusionBrain was the most common site of PD in patients treated with nivolumab, and only half of patients progressing on nivolumab were able to initiate subsequent treatment. The risk of PD increased with a higher baseline NLR and reduced with a higher baseline eosinophil count.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Abstract INTRODUCTION: To develop a risk-stratification model for cancer-specific survival (CSS) following cytoreductive nephrectomy (CN) in the contemporary era. MATERIALS AND METHODS: A retrospective review was performed of 313 patients who underwent CN for M1 renal cell carcinoma (RCC) from 1990 to 2010. To account for the introduction of targeted therapies, timing of surgery was classified as immunotherapy era (1990-2004) or contemporary era (2005-2010). Risk scores were developed to predict CSS using Cox proportional hazards regression models. RESULTS: A total of 215 (69%) and 98 (31%) patients were...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, J. Cózar-OlmoAbstractObjectiveTo put forth new findings of urologic oncology with an impact on clinical practice presented during 2017 in the main annual meetings.MethodsThis document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee.ResultsAmong...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
ConclusionsWe present tumor size-based estimates of the probability of aggressive histology for renal masses. This information should be useful for initial patient counseling and management.Patient summaryActive surveillance is an option for kidney masses, even if they are malignant. Beyond knowing whether the mass is benign or cancer, it is important to know whether or not it is an aggressive tumor. This study presents tumor size-specific and sex-specific estimates of the probability of cancer overall and aggressive cancer among patients with a kidney mass in order to aid with initial decision-making.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Wang Y, Ding Y, Wang J, Gu M, Wang Z, Qin C, Han C, Li H, Liu X, Wu P, Li G Abstract Clear cell papillary renal cell carcinoma (CCPRCC) is a recently recognized subtype of renal cell carcinoma entity, however, little is known about its clinical features. In the present study, 26 cases of CCPRCC were screened out from two institutions. The patient data, tissue pathology, immunohistochemical phenotype, computed tomographic images and survival analysis were studied. The mean age was 53.3 years and the average tumor size was 2.5 cm. A total of 17 patients' body mass indexes were higher than the normal level. A...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Kidney Cancer | Radiography | Renal Cell Carcinoma | Urology & Nephrology